QURE
AI MemoPost-earnings T+1uniQure
As of 2026-11-05/Post-earnings T+1/Confidence medium
Data freshness
AI Memo
As of 2026-11-05 • Model: RankAlpha Sentiment Codex
Decision Panel
Action, confidence, horizon, and decision blockers at a glance.
Action
—
Confidence
medium
Horizon
—
Key catalyst
AMT-130 confirmatory-study screening • 2026-12-31
Base target: $28 / p=45% prob
Biggest risk
The BLA relies on a small high-dose cohort and external control; the 48-month cUHDRS comparison was not statistically significant (p=0.144). FDA approval and confirmatory-trial execution remain binary risks. Q3 revenue of $5.2 million missed the approximately $6.2 million FactSet estimate reported by MarketScreener, while published EPS consensus figures conflict. [#SEC-8K-2026-11-04] https://www.marketscreener.com/quote/stock/UNIQURE-N-V-15712155/news/
Invalidation
Break below $11 or thesis failure.
What would change my mind?
The thesis has strengthened since the May baseline: AMT-130 now has an accepted BLA, Priority Review, a dated FDA decision, and a defined confirmatory-study plan. Q3 cash and investments of $768.4 million underpin management's stated runway into 2030. [#SEC-8K-2026-11-04]
Research note
Recommendation
—
Confidence
medium
As of
2026-11-05
Base target
$28
p=45%
Bull target
$43
p=30%
Bear target
$11
p=25%
Key bullets
Fast scan of bull, bear, and watch items
BullKey bullets
- AMT-260 epilepsy data
- AMT-191 Fabry data and safety
- The thesis has strengthened since the May baseline: AMT-130 now has an accepted BLA, Priority Review, a dated FDA decision, and a defined confirmatory-study plan.
BearKey bullets
- AMT-130's 48-month cUHDRS external-control comparison was non-significant, and the confirmatory trial requires substantial recruitment and follow-up.
- [#SEC-8K-2026-11-04]
- AMT-191 dosing had previously paused after asymptomatic liver-enzyme elevations in two patients; renewed safety findings could slow development.
WatchKey bullets
- AMT-130 confirmatory-study screening
Summary
High-level snapshot
Recommendation
-
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
Post-earnings T+1
Base case: $28 (p=45%)
Target spread vs base: +54% / -61%
Scenario probabilities
Bull Target: $43 (p=30%)Base Target: $28 (p=45%)Bear Target: $11 (p=25%)
Commentary
Early T+1 tone is mixed rather than unreservedly bullish. The company release confirms meaningful regulatory progress and longer projected runway, but Q3 revenue missed a reported FactSet estimate. QURE closed November 4 at $23.03, down 3.52% according to MarketScreener, after an initially positive premarket reaction reported by Investing.com; that reversal should not be attributed to a single cause without stronger evidence. Published EPS-consensus figures disagree, and verified post-print analyst target revisions are unavailable. https://www.marketscreener.com/quote/stock/UNIQURE-N-V-15712155/news/ https://www.investing.com/news/transcripts/earnings-call-transcript-uniqure-posts-q3-2026-eps-beat-as-fda-review-advances-93CH-4999868
As of 2026-11-05 • Updated bi-weekly / post-earningsSource: Internal modelMethodology
Analyst Summary
Thesis highlights from the latest analysis
Bull Case
The thesis has strengthened since the May baseline: AMT-130 now has an accepted BLA, Priority Review, a dated FDA decision, and a defined confirmatory-study plan. Q3 cash and investments of $768.4 million underpin management's stated runway into 2030. [#SEC-8K-2026-11-04]
Bear Case
The BLA relies on a small high-dose cohort and external control; the 48-month cUHDRS comparison was not statistically significant (p=0.144). FDA approval and confirmatory-trial execution remain binary risks. Q3 revenue of $5.2 million missed the approximately $6.2 million FactSet estimate reported by MarketScreener, while published EPS consensus figures conflict. [#SEC-8K-2026-11-04] https://www.marketscreener.com/quote/stock/UNIQURE-N-V-15712155/news/
Drivers
Scannable catalysts and supporting factors
- AMT-260 epilepsy data
- AMT-191 Fabry data and safety
Scenarios
Bull Target (Scenario probability)
$43 / p=30% prob
Base Target (Scenario probability)
$28 / p=45% prob
Bear Target (Scenario probability)
$11 / p=25% prob
Analysis 2026-11-05 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.
Sentiment & Exposure
News Sentiment (30d)
0.35
Social Sentiment (7d)
0.00
Events
Other notable items detected
- EVENT2026-12-31AMT-130 confirmatory-study screeningManagement expects U.S. patient screening by year-end 2026 for an approximately 200-patient, standard-of-care-controlled study. Timely initiation matters to the accelerated-approval pathway, though enrollment and execution remain uncertain. [#SEC-8K-2026-11-04]Prob 75.00% • Move 8.00% • Priced-in 60.00%
- EVENT2027-05-01AMT-130 FDA decisionThe Q3 earnings release confirmed FDA Priority Review of the Huntington's disease BLA and a May 1, 2027 target action date. Approval would materially change the commercial outlook, but acceptance for review is not approval. [#8-K-2026-11-04] [#SEC-8K-2026-11-04]Prob 55.00% • Move 45.00% • Priced-in 55.00%
Short-term Catalysts
Next few weeks
No short-term catalysts
Long-term Catalysts
Months to a year
- AMT-260 epilepsy data2027-06-30After completing enrollment of the seven-patient second dose cohort, uniQure expects updated Phase I/IIa results in the first half of 2027. This could diversify a thesis currently dominated by AMT-130. [#SEC-8K-2026-11-04]Prob 70% • Move 12% • Priced-in 25%
- AMT-191 Fabry data and safety2027-06-30The company expects updated Phase I/II results across dosing cohorts in the first half of 2027. Prior asymptomatic liver-enzyme elevations in two mid-dose patients make safety follow-up especially important. [#SEC-8K-2026-11-04]Prob 65% • Move 10% • Priced-in 20%
Risks
- AMT-130's 48-month cUHDRS external-control comparison was non-significant, and the confirmatory trial requires substantial recruitment and follow-up. [#SEC-8K-2026-11-04]
- AMT-191 dosing had previously paused after asymptomatic liver-enzyme elevations in two patients; renewed safety findings could slow development. [#SEC-8K-2026-11-04]
- Commercial-launch preparation raised Q3 SG&A, while the royalty-financing liability and debt complicate a simple cash-only valuation. [#SEC-8K-2026-11-04]
- FDA could find the AMT-130 Phase I/II evidence insufficient despite accepting the BLA for review; approval is not assured. [#SEC-8K-2026-11-04]
Peers
| Symbol | Summary |
|---|---|
| RGNX | An AAV gene-therapy regulatory and platform comparator, not a same-indication valuation peer. Its program mix and funding position differ materially. Company context: https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-highlights-key-2026-catalysts-and-announces-positive/ |
| TSHA | A closer CNS-focused AAV gene-therapy development comparator, but its Rett syndrome indication and trial stage differ from uniQure's Huntington's disease BLA. Company context: https://tayshagtx.gcs-web.com/ |
Sources
Internal and external references used in this analysis
- Model source: RankAlpha Sentiment Codex
- Analysis date: 2026-11-05